RFG
SUPN icon

RFP Financial Group’s Supernus Pharmaceuticals SUPN Stock Holding History

RFP Financial Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-27
Closed -$722 – 709
2024
Q2 		$722 Hold
27
– – ﹤0.01% 838
2024
Q1 		$921 Hold
27
– – ﹤0.01% 777
2023
Q4 		$781 Hold
27
– – ﹤0.01% 806
2023
Q3 		$744 Hold
27
– – ﹤0.01% 825
2023
Q2 		$812 Hold
27
– – ﹤0.01% 846
2023
Q1 		$978 Hold
27
– – ﹤0.01% 635
2022
Q4 		$963 Buy
+27
New +$938 ﹤0.01% 783

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RFP Financial Group's SUPN Position: Q3 2024 in Review

RFP Financial Group sold out of Supernus Pharmaceuticals (SUPN) in Q3 2024, closing a stake of 27 shares — an estimated $722 sold.

RFP Financial Group first reported a position in SUPN in Q4 2022 and held it in 7 quarters. The position peaked at $978 in Q1 2023. 273 funds tracked by Wall St. Rank hold SUPN as of Q3 2024.

  • RFP Financial Group reported no remaining Supernus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • RFP Financial Group sold 27 Supernus Pharmaceuticals shares in Q3 2024, an estimated $722.
  • RFP Financial Group first reported a position in Supernus Pharmaceuticals in Q4 2022 and held it in 7 quarters.
  • RFP Financial Group's Supernus Pharmaceuticals position peaked at $978 in Q1 2023.
  • 273 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2024.

Based on RFP Financial Group's 13F filing for Q3 2024, filed 21 Oct 2024.